Current status of prognostication in classical Hodgkin lymphoma

British Journal of Haematology

Volumn 165, Issue 3, 2014, Pages 287-299

  Venkataraman, Girish ^a   Mirza, M Kamran ^a   Eichenauer, Dennis A ^b,c   Diehl, Volker ^c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c German Hodgkin Study Group (GHSG)   (Germany)

Author keywords

Classical Hodgkin lymphoma; Clinical risk factors; Genome expression profiling; Immunohistochemistry; Prognosis; Serum biomarkers

Indexed keywords

BLEOMYCIN; CD30 ANTIGEN; CHLORDANE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GALECTIN 1; MICRORNA; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; ARTICLE; CANCER PROGNOSIS; CLASSICAL HODGKIN LYMPHOMA; DRUG DOSE ESCALATION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE RICH HODGKIN LYMPHOMA; MIXED CELLULARITY HODGKIN LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REED STERNBERG CELL; RISK FACTOR; YOUNG ADULT;

CLASSICAL HODGKIN LYMPHOMA; CLINICAL RISK FACTORS; GENOME EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; PROGNOSIS; SERUM BIOMARKERS;

GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

EID: 84898443557     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12759     Document Type: Article

References (107)

1. Alvaro, T., Lejeune, M., Salvado, M.T., Bosch, R., Garcia, J.F., Jaen, J., Banham, A.H., Roncador, G., Montalban, C. & Piris, M.A. (2005) Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clinical Cancer Research, 11, 1467-1473.
2. Arai, S., Fanale, M., Devos, S., Engert, A., Illidge, T., Borchmann, P., Younes, A., Morschhauser, F., McMillan, A. & Horning, S. (2013) Defining a Hodgkin Lymphoma Population for Novel Therapeutics after Relapse from Autologous Hematopoietic Cell Transplantation. Leukaemia & Lymphoma, 54, 2531-2533.
3. Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S.R., Morris, L.E., Holland, H.K., Mason, J.R., Alyea, E.P., Soiffer, R.J. & Ball, E.D. (2009) CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood, 113, 1581-1588.
4. Bennett, M.H., MacLennan, K.A., Easterling, M.J., Vaughan Hudson, B., Jelliffe, A.M. & Vaughan Hudson, G. (1983) The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22). Clinical Radiology, 34, 497-501.
5. Borchmann, P., Eichenauer, D.A. & Engert, A. (2012) State of the art in the treatment of Hodgkin lymphoma. Nature Reviews. Clinical oncology, 9, 450-459.
6. Brauninger, A., Kuppers, R., Strickler, J., Wacker, H., Rajewsky, K. & Hansmann, M.-L. (1997) Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proceedings of the National Academy of Sciences of the United States of America, 94, 9337-9342.
7. Brune, V., Tiacci, E., Pfeil, I., Doring, C., Eckerle, S., van Noesel, C.J., Klapper, W., Falini, B., von Heydebreck, A., Metzler, D., Brauninger, A., Hansmann, M.L. & Kuppers, R. (2008) Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. Journal of Experimental Medicine, 205, 2251-2268.
8. Buglio, D., Georgakis, G.V., Hanabuchi, S., Arima, K., Khaskhely, N.M., Liu, Y.J. & Younes, A. (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood, 112, 1424-1433.
9. Chetaille, B., Bertucci, F., Finetti, P., Esterni, B., Stamatoullas, A., Picquenot, J.M., Copin, M.C., Morschhauser, F., Casasnovas, O., Petrella, T., Molina, T., Vekhoff, A., Feugier, P., Bouabdallah, R., Birnbaum, D., Olive, D. & Xerri, L. (2009) Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood, 113, 2765-3775.
10. de la Cruz-Merino, L., Lejeune, M., Nogales Fernandez, E., Henao Carrasco, F., Grueso Lopez, A., Illescas Vacas, A., Pulla, M.P., Callau, C. & Alvaro, T. (2012) Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implications. Clinical & Developmental Immunology, 2012, 756353.
11. Delsol, G., Brousset, P., Chittal, S. & Rigal-Huguet, F. (1992) Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated BamHI-W probes in Hodgkin's disease. American Journal of Pathology, 140, 247-253.
12. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dorken, B., Muller-Hermelink, H.K., Duhmke, E. & Loeffler, M. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386-2395.
13. Eichenauer, D.A., Engert, A. & Dreyling, M. (2011) Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 22(Suppl 6), vi55-vi58.
14. Emmert-Buck, M.R., Bonner, R.F., Smith, P.D., Chuaqui, R.F., Zhuang, Z., Goldstein, S.R., Weiss, R.A. & Liotta, L.A. (1996) Laser capture microdissection. Science, 274, 998-1001.
15. Engert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Kral, Z., Fuchs, M., Hallek, M., Kanz, L., Dohner, H., Dorken, B., Engel, N., Topp, M., Klutmann, S., Amthauer, H., Bockisch, A., Kluge, R., Kratochwil, C., Schober, O., Greil, R., Andreesen, R., Kneba, M., Pfreundschuh, M., Stein, H., Eich, H.T., Muller, R.P., Dietlein, M., Borchmann, P. & Diehl, V. (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379, 1791-1799.
16. Ferry, J.A., Linggood, R.M., Convery, K.M., Efird, J.T., Eliseo, R. & Harris, N.L. (1993) Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer, 71, 457-463.
17. Gaiolla, R.D., Domingues, M.A., Niero-Melo, L. & de Oliveira, D.E. (2011) Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Archives of Pathology and Laboratory Medicine, 135, 483-489.
18. Galdiero, M.R., Bonavita, E., Barajon, I., Garlanda, C., Mantovani, A. & Jaillon, S. (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology, 218, 1402-1410.
19. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
20. Geiss, G.K., Bumgarner, R.E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D.L., Fell, H.P., Ferree, S., George, R.D., Grogan, T., James, J.J., Maysuria, M., Mitton, J.D., Oliveri, P., Osborn, J.L., Peng, T., Ratcliffe, A.L., Webster, P.J., Davidson, E.H., Hood, L. & Dimitrov, K. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature Biotechnology, 26, 317-325.
21. Greaves, P., Clear, A., Coutinho, R., Wilson, A., Matthews, J., Owen, A., Shanyinde, M., Lister, T.A., Calaminici, M. & Gribben, J.G. (2013a) Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. Journal of Clinical Oncology, 31, 256-262.
22. Greaves, P., Clear, A., Owen, A., Iqbal, S., Lee, A., Matthews, J., Wilson, A., Calaminici, M. & Gribben, J.G. (2013b) Defining characteristics of classical Hodgkin lymphoma microenvironment T helper cells. Blood, 122, 2856-2863.
23. Green, M.R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D. & Shipp, M.A. (2012) Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical Cancer Research, 18, 1611-1618.
24. Hartmann, S., Martin-Subero, J.I., Gesk, S., Husken, J., Giefing, M., Nagel, I., Riemke, J., Chott, A., Klapper, W., Parrens, M., Merlio, J.P., Kuppers, R., Brauninger, A., Siebert, R. & Hansmann, M.L. (2008) Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica, 93, 1318-1326.
25. Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506-1514.
26. Hnatkova, M., Mocikova, H., Trneny, M. & Zivny, J. (2009) The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC. Prague Medical Report, 110, 35-41.
27. Hodgkin, T. (1832) On some morbid experiences of the absorbent glands and spleen. Medico-Chirurgical Transactions, 17, 68-97.
28. Hohaus, S., Santangelo, R., Giachelia, M., Vannata, B., Massini, G., Cuccaro, A., Martini, M., Cesarini, V., Cenci, T., D'Alo, F., Voso, M.T., Fadda, G., Leone, G. & Larocca, L.M. (2011) The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clinical Cancer Research, 17, 2885-2892.
29. Hohaus, S., Giachelia, M., Cupelli, E., Cuccaro, A., Massini, G., Bartolomei, F., D'Alò, F., Voso, M.T. & Leone, G. (2013) Quantitative and qualitative evaluation of circulating cell-free DNA as a prognostic biomarker in Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), 122, 4242.
30. Hoppe, R.T., Advani, R.H., Ai, W.Z., Ambinder, R.F., Aoun, P., Bello, C.M., Bierman, P.J., Blum, K.A., Chen, R., Dabaja, B., Duron, Y., Forero, A., Gordon, L.I., Hernandez-Ilizaliturri, F.J., Hochberg, E.P., Maloney, D.G., Mansur, D., Mauch, P.M., Metzger, M., Moore, J.O., Morgan, D., Moskowitz, C.H., Poppe, M., Pro, B., Winter, J.N., Yahalom, J. & Sundar, H. (2012) Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network, 10, 589-597.
31. Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.M., Berthelsen, A.K. & Specht, L. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, 52-59.
32. Inoue, S., Leitner, W.W., Golding, B. & Scott, D. (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Research, 66, 7741-7747.
33. Jones, R.J., Gocke, C.D., Kasamon, Y.L., Miller, C.B., Perkins, B., Barber, J.P., Vala, M.S., Gerber, J.M., Gellert, L.L., Siedner, M., Lemas, M.V., Brennan, S., Ambinder, R.F. & Matsui, W. (2009) Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood, 113, 5920-5926.
34. Jones, K., Nourse, J.P., Keane, C., Bhatnagar, A. & Gandhi, M.K. (2014) Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma. Clinical Cancer Research, 20, 253-264.
35. Josting, A., Rueffer, U., Franklin, J., Sieber, M., Diehl, V. & Engert, A. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood, 96, 1280-1286.
36. Josting, A., Franklin, J., May, M., Koch, P., Beykirch, M.K., Heinz, J., Rudolph, C., Diehl, V. & Engert, A. (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. Journal of Clinical Oncology, 20, 221-230.
37. Juszczynski, P., Ouyang, J., Monti, S., Rodig, S.J., Takeyama, K., Abramson, J., Chen, W., Kutok, J.L., Rabinovich, G.A. & Shipp, M.A. (2007) The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 104, 13134-13139.
38. Kamper, P., Ludvigsen, M., Bendix, K., Hamilton-Dutoit, S., Rabinovich, G.A., Moller, M.B., Nyengaard, J.R., Honore, B. & d'Amore, F. (2011) Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood, 117, 6638-6649.
39. Kanzler, H., Hansmann, M.L., Kapp, U., Wolf, J., Diehl, V., Rajewsky, K. & Kuppers, R. (1996a) Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood, 87, 3429-3436.
40. Kanzler, H., Kuppers, R., Hansmann, M.L. & Rajewsky, K. (1996b) Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. Journal of Experimental Medicine, 184, 1495-1505.
41. Koreishi, A.F., Saenz, A.J., Persky, D.O., Cui, H., Moskowitz, A., Moskowitz, C.H. & Teruya-Feldstein, J. (2010) The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Applied Immunohistochemistry & Molecular Morphology, 18, 206-211.
42. Kosmaczewska, A., Frydecka, I., Bocko, D., Ciszak, L. & Teodorowska, R. (2002) Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production. British Journal of Haematology, 118, 202-209.
43. Kowalska, M., Tajer, J., Chechlinska, M., Fuksiewicz, M., Kotowicz, B., Kaminska, J. & Walewski, J. (2012) Serum macrophage colony-stimulating factor (M-CSF) in patients with Hodgkin lymphoma. Medical Oncology, 29, 2143-2147.
44. Kuppers, R. (2009) Molecular biology of Hodgkin lymphoma. Hematology/the Education Program of the American Society of Hematology, 2009, 491-496.
45. Kuppers, R., Zhao, M., Hansmann, M.L. & Rajewsky, K. (1993) Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO Journal, 12, 4955-4967.
46. Kuppers, R., Rajewsky, K., Zhao, M., Simons, G., Laumann, R., Fischer, R. & Hansmann, M. (1994) Hodgkin's disease: Hodgkin and Reed Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proceedings of the National Academy of Sciences of the United States of America, 91, 1092-1096.
47. Kuppers, R., Kanzler, H., Hansmann, M.L. & Rajewsky, K. (1996) Single cell analysis of Hodgkin/Reed-Sternberg cells. Annals of Oncology, 7, 27-30.
48. Kuppers, R., Hansmann, M.L. & Rajewsky, K. (1998) Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease. Annals of Oncology, 9, S17-S20.
49. Kuppers, R., Schwering, I., Brauninger, A., Rajewsky, K. & Hansmann, M.L. (2002) Biology of Hodgkin's lymphoma. Annals of Oncology, 13, 11-18.
50. Kuppers, R., Klein, U., Schwering, I., Distler, V., Brauninger, A., Cattoretti, G., Tu, Y., Stolovitzky, G.A., Califano, A., Hansmann, M.L. & Dalla-Favera, R. (2003) Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. The Journal of Clinical Investigation, 111, 529-537.
51. Lamprecht, B., Walter, K., Kreher, S., Kumar, R., Hummel, M., Lenze, D., Kochert, K., Bouhlel, M.A., Richter, J., Soler, E., Stadhouders, R., Johrens, K., Wurster, K.D., Callen, D.F., Harte, M.F., Giefing, M., Barlow, R., Stein, H., Anagnostopoulos, I., Janz, M., Cockerill, P.N., Siebert, R., Dorken, B., Bonifer, C. & Mathas, S. (2010) Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nature Medicine, 16, 571-579.
52. Loddenkemper, C., Anagnostopoulos, I., Hummel, M., Johrens-Leder, K., Foss, H.D., Jundt, F., Wirth, T., Dorken, B. & Stein, H. (2004) Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. The Journal of Pathology, 202, 60-69.
53. Marri, P., Hodge, L.S., Maurer, M.J., Ziesmer, S.C., Slager, S.L., Habermann, T.M., Link, B.K., Cerhan, J.R., Novak, A.J. & Ansell, S.M. (2013) Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clinical Cancer Research, 19, 6812-6819.
54. Marshall, N.A., Christie, L.E., Munro, L.R., Culligan, D.J., Johnston, P.W., Barker, R.N. & Vickers, M.A. (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 103, 1755-1762.
55. Martinez, C., Canals, C., Sarina, B., Alessandrino, E.P., Karakasis, D., Pulsoni, A., Sica, S., Trneny, M., Snowden, J.A., Kanfer, E., Milpied, N., Bosi, A., Guidi, S., de Souza, C.A., Willemze, R., Arranz, R., Jebavy, L., Hellmann, A., Sibon, D., Oneto, R., Luan, J.J., Dreger, P., Castagna, L. & Sureda, A. (2013) Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Annals of Oncology, 24, 2430-2434.
56. Moccia, A.A., Donaldson, J., Chhanabhai, M., Hoskins, P.J., Klasa, R.J., Savage, K.J., Shenkier, T.N., Slack, G.W., Skinnider, B., Gascoyne, R.D., Connors, J.M. & Sehn, L.H. (2012) International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. Journal of Clinical Oncology, 30, 3383-3388.
57. Montalban, C., Abraira, V., Morente, M., Acevedo, A., Aguilera, B., Bellas, C., Fraga, M., Del Moral, R.G., Menarguez, J., Oliva, H., Sanchez-Beato, M. & Piris, M.A. (2000) Epstein-Barr virus-latent membrane protein 1 expression has a favorable influence in the outcome of patients with Hodgkin's Disease treated with chemotherapy. Leukaemia & Lymphoma, 39, 563-572.
58. Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., Louie, D., Gonzales, M., Walits, J., Coady-Lyons, N., Qin, J., Frank, R., Bertino, J.R., Goy, A., Noy, A., O'Brien, J.P., Straus, D., Portlock, C.S. & Yahalom, J. (2001) A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 97, 616-623.
59. Moskowitz, A.J., Perales, M.A., Kewalramani, T., Yahalom, J., Castro-Malaspina, H., Zhang, Z., Vanak, J., Zelenetz, A.D. & Moskowitz, C.H. (2009) Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. British Journal of Haematology, 146, 158-163.
60. Moskowitz, A.J., Yahalom, J., Kewalramani, T., Maragulia, J.C., Vanak, J.M., Zelenetz, A.D. & Moskowitz, C.H. (2010) Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood, 116, 4934-4937.
61. Moskowitz, C.H., Younes, A., de Vos, S., Bociek, R.G., Gordon, L.I., Witzig, T.E., Gascoyne, R., West, B., Nolop, K. & Steidl, C. (2012) CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: results From a Phase 2 Single Agent Clinical Trial. Blood (ASH Annual Meeting Abstracts), 120, 1638.
62. Nakajima, Y., Tomita, N., Watanabe, R., Ishiyama, Y., Yamamoto, E., Ishibashi, D., Itabashi, M., Koyama, S., Takahashi, H., Numata, A., Takasaki, H., Kawasaki, R., Kuwabara, H., Tanaka, M., Hashimoto, C., Fujimaki, K., Sakai, R., Motomura, S. & Ishigatsubo, Y. (2013) Serum beta-2 microglobulin level as a useful prognostic marker of Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), 122, 4239.
63. Oki, Y. & Younes, A. (2010) Does rituximab have a place in treating classic hodgkin lymphoma? Current Hematologic Malignancy Reports, 5, 135-139.
64. Ouyang, J., Plutschow, A., Pogge von Strandmann, E., Reiners, K.S., Ponader, S., Rabinovich, G.A., Neuberg, D., Engert, A. & Shipp, M.A. (2013) Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood, 121, 3431-3433.
65. Peggs, K.S., Anderlini, P. & Sureda, A. (2008) Allogeneic transplantation for Hodgkin lymphoma. British Journal of Haematology, 143, 468-480.
66. Petrella, T., Michiels, J.F., Michiels, R., Collin, F., Nabholtz, J.M., Friedman, S. & Fargeot, P. (1989) CD 15 antigen in Hodgkin's disease. Pathology, Research and Practice, 185, 886-890.
67. Plattel, W.J., van den Berg, A., Visser, L., van der Graaf, A.M., Pruim, J., Vos, H., Hepkema, B., Diepstra, A. & van Imhoff, G.W. (2012) Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma. Haematologica, 97, 410-415.
68. Portlock, C.S., Donnelly, G.B., Qin, J., Straus, D., Yahalom, J., Zelenetz, A., Noy, A., O'Connor, O., Horwitz, S., Moskowitz, C. & Filippa, D.A. (2004) Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. British Journal of Haematology, 125, 701-708.
69. Radford, J., Barrington, S., Counsell, N., Pettengell, R., Johnson, P., Wimperis, J., Coltart, S., Culligan, D., Lister, A., Bessell, E., Kruger, A., Popova, B., Hancock, B., Hoskin, P., Illidge, T. & O'Doherty, M. (2012) Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'Negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID trial. Blood (ASH Annual Meeting Abstracts), 120, 547.
70. Rassidakis, G.Z., Medeiros, L.J., Viviani, S., Bonfante, V., Nadali, G.P., Vassilakopoulos, T.P., Mesina, O., Herling, M., Angelopoulou, M.K., Giardini, R., Chilosi, M., Kittas, C., McLaughlin, P., Rodriguez, M.A., Romaguera, J., Bonadonna, G., Gianni, A.M., Pizzolo, G., Pangalis, G.A., Cabanillas, F. & Sarris, A.H. (2002) CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. Journal of Clinical Oncology, 20, 1278-1287.
71. Sanchez-Espiridion, B., Sanchez-Aguilera, A., Montalban, C., Martin, C., Martinez, R., Gonzalez-Carrero, J., Poderos, C., Bellas, C., Fresno, M.F., Morante, C., Mestre, M.J., Mendez, M., Mazorra, F., Conde, E., Castano, A., Sanchez-Godoy, P., Tomas, J.F., Morente, M.M., Piris, M.A. & Garcia, J.F. (2009) A TaqMan low-density array to predict outcome in advanced Hodgkin's lymphoma using paraffin-embedded samples. Clinical Cancer Research, 15, 1367-1375.
72. Sanchez-Espiridion, B., Montalban, C., Lopez, A., Menarguez, J., Sabin, P., Ruiz-Marcellan, C., Ramos, R., Rodriguez, J., Canovas, A., Camarero, C., Canales, M., Alves, J., Arranz, R., Acevedo, A., Salar, A., Serrano, S., Bas, A., Moraleda, J.M., Sanchez-Godoy, P., Burgos, F., Rayon, C., Fresno, M.F., Larana, J.G., Garcia-Cosio, M., Santonja, C., Lopez, J.L., Llanos, M., Mollejo, M., Gonzalez-Carrero, J., Marin, A., Forteza, J., Garcia-Sanz, R., Tomas, J.F., Morente, M.M., Piris, M.A. & Garcia, J.F. (2010) A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood, 116, e12-e17.
73. Sanchez-Espiridion, B., Martin-Moreno, A.M., Montalban, C., Figueroa, V., Vega, F., Younes, A., Medeiros, L.J., Alves, F.J., Canales, M., Estevez, M., Menarguez, J., Sabin, P., Ruiz-Marcellan, M.C., Lopez, A., Sanchez-Godoy, P., Burgos, F., Santonja, C., Lopez, J.L., Piris, M.A. & Garcia, J.F. (2013) MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. British Journal of Haematology, 162, 336-347.
74. Sauer, M., Plutschow, A., Jachimowicz, R.D., Kleefisch, D., Reiners, K.S., Ponader, S., Engert, A. & von Strandmann, E.P. (2013) Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. American Journal of Hematology, 88, 113-115.
75. Schiavoni, G., Gabriele, L. & Mattei, F. (2013) The tumor microenvironment: a pitch for multiple players. Frontiers in Oncology, 3, 90.
76. Schmitz, R., Stanelle, J., Hansmann, M.L. & Kuppers, R. (2009) Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annual Review of Pathology, 4, 151-174.
77. Schreck, S., Friebel, D., Buettner, M., Distel, L., Grabenbauer, G., Young, L.S. & Niedobitek, G. (2009) Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematological Oncology, 27, 31-39.
78. Scott, D.W., Chan, F.C., Hong, F., Rogic, S., Tan, K.L., Meissner, B., Ben-Neriah, S., Boyle, M., Kridel, R., Telenius, A., Woolcock, B.W., Farinha, P., Fisher, R.I., Rimsza, L.M., Bartlett, N.L., Cheson, B.D., Shepherd, L.E., Advani, R.H., Connors, J.M., Kahl, B.S., Gordon, L.I., Horning, S.J., Steidl, C. & Gascoyne, R.D. (2013) Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. Journal of Clinical Oncology, 31, 692-700.
79. Shimabukuro-Vornhagen, A., Haverkamp, H., Engert, A., Balleisen, L., Majunke, P., Heil, G., Eich, H.T., Stein, H., Diehl, V. & Josting, A. (2005) Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. Journal of Clinical Oncology, 23, 5739-5745.
80. Skinnider, B.F. & Mak, T.W. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, 4283-4297.
81. Skoetz, N., Trelle, S., Rancea, M., Haverkamp, H., Diehl, V., Engert, A. & Borchmann, P. (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. The Lancet Oncology, 14, 943-952.
82. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., Bast, M.A., Rosenwald, A., Muller-Hermelink, H.K., Rimsza, L.M., Campo, E., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Lenz, G., Connors, J.M., Staudt, L.M., Chan, W.C. & Gascoyne, R.D. (2010a) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New England Journal of Medicine, 362, 875-885.
83. Steidl, C., Telenius, A., Shah, S.P., Farinha, P., Barclay, L., Boyle, M., Connors, J.M., Horsman, D.E. & Gascoyne, R.D. (2010b) Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood, 116, 418-427.
84. Steidl, C., Connors, J.M. & Gascoyne, R.D. (2011) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Journal of Clinical Oncology, 29, 1812-1826.
85. Steidl, C., Diepstra, A., Lee, T., Chan, F.C., Farinha, P., Tan, K., Telenius, A., Barclay, L., Shah, S.P., Connors, J.M., van den Berg, A. & Gascoyne, R.D. (2012) Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood, 120, 3530-3540.
86. Stein, H., Marafioti, T., Foss, H.D., Laumen, H., Hummel, M., Anagnostopoulos, I., Wirth, T., Demel, G. & Falini, B. (2001) Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood, 97, 496-501.
87. Sureda, A., Canals, C., Arranz, R., Caballero, D., Ribera, J.M., Brune, M., Passweg, J., Martino, R., Valcarcel, D., Besalduch, J., Duarte, R., Leon, A., Pascual, M.J., Garcia-Noblejas, A., Lopez Corral, L., Xicoy, B., Sierra, J. & Schmitz, N. (2012) Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 97, 310-317.
88. Swerdlow, S.H., Campo, E. & Harris, N.L. (2008) WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC press, Lyons, France.
89. Tan, K.L., Scott, D.W., Hong, F., Kahl, B.S., Fisher, R.I., Bartlett, N.L., Advani, R.H., Buckstein, R., Rimsza, L.M., Connors, J.M., Steidl, C., Gordon, L.I., Horning, S.J. & Gascoyne, R.D. (2012) Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood, 120, 3280-3287.
90. Thompson, C.A., Maurer, M.J., Cerhan, J.R., Katzmann, J.A., Ansell, S.M., Habermann, T.M., Macon, W.R., Weiner, G.J., Link, B.K. & Witzig, T.E. (2011) Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. American Journal of Hematology, 86, 998-1000.
91. Tiacci, E., Doring, C., Brune, V., van Noesel, C.J., Klapper, W., Mechtersheimer, G., Falini, B., Kuppers, R. & Hansmann, M.L. (2012) Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood, 120, 4609-4620.
92. von Tresckow, B., Skotnicki, A., Lisukov, I., Srivastava, S., Morgan, D., Morschhauser, F., Stelitano, C., Szer, J., Eichenauer, D.A., Abramson, J., Sureda, A., Ferme, C. & Engert, A. (2013a) A Phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Blood (ASH Annual Meeting Abstracts), 122, 4648.
93. von Tresckow, B., Muller, H., Eichenauer, D.A., Glossmann, J.P., Josting, A., Boll, B., Klimm, B., Sasse, S., Fuchs, M., Borchmann, P. & Engert, A. (2013b) Outcome and risk factors of Hodgkin Lymphoma patients who relapse or progress after autologous stem cell transplant. Leukaemia & Lymphoma. doi: 10.3109/10428194.2013.854888. [Epub ahead of print].
94. Tzankov, A., Krugmann, J., Fend, F., Fischhofer, M., Greil, R. & Dirnhofer, S. (2003) Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clinical Cancer Research, 9, 1381-1386.
95. Tzankov, A., Matter, M.S. & Dirnhofer, S. (2010) Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular Micromilieu of classical hodgkin lymphoma. Pathobiology, 77, 301-308.
96. Ushmorov, A., Leithauser, F., Sakk, O., Weinhausel, A., Popov, S.W., Moller, P. & Wirth, T. (2006) Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood, 107, 2493-2500.
97. van den Berg, A., Visser, L. & Poppema, S. (1999) High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. American Journal of Pathology, 154, 1685-1691.
98. van Spronsen, D.J., Vrints, L.W., Hofstra, G., Crommelin, M.A., Coebergh, J.W. & Breed, W.P. (1997) Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkinņs disease for unselected patients, 1972-92. British Journal of Haematology, 96, 322-327.
99. Van Vlierberghe, P., De Weer, A., Mestdagh, P., Feys, T., De Preter, K., De Paepe, P., Lambein, K., Vandesompele, J., Van Roy, N., Verhasselt, B., Poppe, B. & Speleman, F. (2009) Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. British Journal of Haematology, 147, 686-690.
100. Vassilakopoulos, T.P., Nadali, G., Angelopoulou, M.K., Siakantaris, M.P., Dimopoulou, M.N., Kontopidou, F.N., Rassidakis, G.Z., Doussis-Anagnostopoulou, I.A., Hatzioannou, M., Vaiopoulos, G., Kittas, C., Sarris, A.H., Pizzolo, G. & Pangalis, G.A. (2001) Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Haematologica, 86, 274-281.
101. Venkataraman, G., Song, J.Y., Tzankov, A., Dirnhofer, S., Heinze, G., Kohl, M., Traverse-Glehen, A., Eberle, F.C., Hanson, J.C., Raffeld, M.A., Pittaluga, S. & Jaffe, E.S. (2013) Aberrant T-cell antigen expression in classical Hodgkin lymphoma is associated with decreased event-free survival and overall survival. Blood, 121, 1795-1804.
102. von Wasielewski, R., Mengel, M., Fischer, R., Hansmann, M.L., Hubner, K., Franklin, J., Tesch, H., Paulus, U., Werner, M., Diehl, V. & Georgii, A. (1997) Classical Hodgkin's disease. Clinical impact of the immunophenotype. American Journal of Pathology, 151, 1123-1130.
103. von Wasielewski, R., Seth, S., Franklin, J., Fischer, R., Hubner, K., Hansmann, M.L., Diehl, V. & Georgii, A. (2000) Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood, 95, 1207-1213.
104. von Wasielewski, S., Franklin, J., Fischer, R., Hubner, K., Hansmann, M.L., Diehl, V., Georgii, A. & von Wasielewski, R. (2003) Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages. Blood, 101, 4063-4069.
105. Willenbrock, K., Ichinohasama, R., Kadin, M.E., Miura, I., Terui, T., Meguro, K., Fukuhara, O., DeCoteau, J.F. & Hansmann, M.L. (2002) T-cell variant of classical Hodgkin's lymphoma with nodal and cutaneous manifestations demonstrated by single-cell polymerase chain reaction. Laboratory Investigation, 82, 1103-1109.
106. Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, K., Kurata, M., Hayashi, T. & Uchiyama, T. (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood, 111, 3220-3224.
107. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L. & Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. New England Journal of Medicine, 363, 1812-1821.